Cara Therapeutics Obtains $15,000,000 Series D Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9ef83f70-8d4a-4cda-bc42-5120615911cd&Preview=1
Date 7/21/2010
Company Name Cara Therapeutics
Mailing Address One Parrott Drive Shelton, CT 06484
Company Description Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara’s first patented compound, CR665, has entered clinical testing for acute pain. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Proceeds Purposes The Series D financing will be used primarily for the continued clinical development of Cara’s lead peripherally restricted kappa opioid agonist, CR845, for the treatment of post-operative pain.